Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if DNA is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
21 top institutions tracked
Last 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoverySentiment: bearish
Last trade: sell 7 days ago
Red flags: 14
182 filers reported a long position in DNA for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| BlackRock, Inc. | $42.4M | 4.3M | +17.6% |
| VIKING GLOBAL INVESTORS LP | $35.4M | 3.6M | Unchanged |
| Erste Asset Management GmbH | $25.9M | 2.5M | +30.3% |
| BAILLIE GIFFORD & CO | $23.7M | 2.4M | Unchanged |
| VANGUARD CAPITAL MANAGEMENT LLC | $20.7M | 2.1M | +9% |
| Anchorage Capital Group, L.L.C. | $17.3M | 1.7M | Unchanged |
| Legal & General Group Plc | $16.5M | 1.7M | +0.5% |
| STATE STREET CORP | $14.6M | 1.5M | +9.3% |
| GEODE CAPITAL MANAGEMENT, LLC | $12.1M | 1.2M | +21.1% |
| FORBES J M & CO LLP | $9.9M | 999.9K | -2.8% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.